From years of working closely with scientists, we at Strand understand that most drug development programs fail at the pre-clinical stage due to poor pharmacokinetics and toxicity.

Strand's innovations in biological systems modeling help you combat failure at the pre-clinical stage.

• Model Inputs

  • Protein level data

    • Interference with enzyme activity (assay with whole cell extract)

    • Indirect interference with enzyme activity (change in protein concentration

    • LC-MS Data

  • Gene expression data

    • Indirect input

    • Assumption that gene expression changes result in pathway perturbation

    • Concordant pathways are perturbed to assess impact of toxicant

  • Metabolite data

    • Direct or indirect inputs

Toxicity Potential Analysis

• Understand extant data (genes, proteins, metabolites) on 3-5 compounds

• Predictive simulation to map compound data upon pathways

• Generate hypotheses on toxicity potential of compounds

• Suggest a set of in vitro experiments to verify nature of toxicity

• Generate a report on the compounds

Off-Target Effect Analysis

• Use targets that have homologues present in liver (potential for liver toxicity)

• Assess impact on pathways that upon dysregulation may lead to hepatotoxic effects

• Recommend a set of experiments/biomarkers to provide experimental validation.

• 
  
  Biomarker Analysis
• 
  
  Hepatotoxicity Model
• 
  
  Image Analysis
• 
  
  Virtual Lab

• 
  
  Systems Biology Modeling